<!--The Official Report of Parliamentary Debates (Hansard) of the Legislative Council and the House of Assembly of the Parliament of South Australia are covered by parliamentary privilege. Republication by others is not afforded the same protection and may result in exposure to legal liability if the material is defamatory. You may copy and make use of excerpts of proceedings where (1) you attribute the Parliament as the source, (2) you assume the risk of liability if the manner of your use is defamatory, (3) you do not use the material for the purpose of advertising, satire or ridicule, or to misrepresent members of Parliament, and (4) your use of the extracts is fair, accurate and not misleading. Copyright in the Official Report of Parliamentary Debates is held by the Attorney-General of South Australia.-->
<hansard id="" tocId="" xml:lang="EN-AU" schemaVersion="4.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xml="http://www.w3.org/XML/1998/namespace" xmlns:xsi="http://www.w3.org/2007/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:noNamespaceSchemaLocation="hansard_1_0.xsd">
  <name>Estimates Committee B - Answers to Questions</name>
  <date date="2013-11-15T00:00:00+10:30" />
  <sessionName>Fifty-Second Parliament, Second Session (52-2)</sessionName>
  <parliamentNum>52</parliamentNum>
  <sessionNum>2</sessionNum>
  <parliamentName>Parliament of South Australia</parliamentName>
  <house>Estimates Committee B - Answers to Questions</house>
  <venue></venue>
  <reviewStage>published</reviewStage>
  <startPage num="5" />
  <endPage num="13" />
  <dateModified time="2023-06-16T13:44:50+09:30" />
  <proceeding continued="true">
    <name>Estimates Replies</name>
    <subject>
      <name>Naltrexone</name>
      <text id="2013111517d0c94a46b54c9d90000051">
        <heading>NALTREXONE</heading>
      </text>
      <talker role="member" id="1807" kind="question">
        <name>In reply to Dr McFETRIDGE</name>
        <house>Legislative Council</house>
        <questions>
          <question date="2013-11-15">
            <name>NALTREXONE</name>
          </question>
        </questions>
        <text id="2013111517d0c94a46b54c9d90000052">In reply to <by role="member" id="1807">Dr McFETRIDGE (Morphett)</by> (26 June 2013).</text>
      </talker>
      <talker role="member" id="627" kind="answer">
        <name>The Hon. J.J. SNELLING</name>
        <house>Legislative Council</house>
        <portfolios>
          <portfolio id="">
            <name>Minister for Health and Ageing</name>
          </portfolio>
          <portfolio id="">
            <name>Minister for Mental Health and Substance Abuse</name>
          </portfolio>
          <portfolio id="">
            <name>Minister for Defence Industries</name>
          </portfolio>
          <portfolio id="">
            <name>Minister for Veterans' Affairs</name>
          </portfolio>
        </portfolios>
        <questions>
          <question date="2013-11-15">
            <name>NALTREXONE</name>
          </question>
        </questions>
        <text id="2013111517d0c94a46b54c9d90000053">
          <by role="member" id="627">The Hon. J.J. SNELLING (Playford—Minister for Health and Ageing, Minister for Mental Health and Substance Abuse, Minister for Defence Industries, Minister for Veterans' Affairs):</by>  There is a range of evidence-based treatment options for opioid dependence available in South Australia which already includes the prescription of oral naltrexone for opioid and alcohol related addiction.</text>
      </talker>
    </subject>
  </proceeding>
</hansard>